|
[1]
|
中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年) [J]. 中华眼科杂志, 2014, 50(11): 851-865.
|
|
[2]
|
Ciulla, T.A., Pollack, J.S. and Williams, D.F. (2021) Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Diabetic Macular Oedema: A Real-World Analysis of 28658 Patient Eyes. British Journal of Ophthalmology, 105, 216-221.
https://doi.org/10.1136/bjophthalmol-2020-315933
|
|
[3]
|
Yau, J.W., Rogers, S.L., Kawasaki, R., et al. (2012) Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care, 35, 556-564.
https://doi.org/10.2337/dc11-1909
|
|
[4]
|
Early Treatment Diabetic Retinopathy Study Research Group (1991) Early Photocoagulation for Diabetic Retinopathy. ETDRS Report Number 9. Ophthalmology, 98, 766-785.
https://doi.org/10.1016/S0161-6420(13)38011-7
|
|
[5]
|
李虹蓉, 汪浩. 糖尿病视网膜神经变性的研究进展[J]. 中华眼底病杂志, 2020, 40(6): 52-57.
|
|
[6]
|
Wisniewska-Kruk, J., van der Wijk, A.E., van Veen, H.A., et al. (2016) Plasmalemma Vesicle-Associated Protein Has a Key Role in Blood-Retinal Barrier Loss. The American Journal of Pathology, 186, 1044-1054.
https://doi.org/10.1016/j.ajpath.2015.11.019
|
|
[7]
|
Liu, X., Dreffs, A., Díaz-Coránguez, M., et al. (2016) Occludin S490 Phosphorylation Regulates Vascular Endothelial Growth Factor-Induced Retinal Neovascularization. The American Journal of Pathology, 186, 2486-2499.
https://doi.org/10.1016/j.ajpath.2016.04.018
|
|
[8]
|
Kim, E.J., Lin, W.V., Rodriguez, S.M., Chen, A., Loya, A. and Weng, C.Y. (2019) Treatment of Diabetic Macular Edema. Current Diabetes Reports, 19, Article No. 68.
https://doi.org/10.1007/s11892-019-1188-4
|
|
[9]
|
Klein, R., Lee, K.E., Gangnon, R.E. and Klein, B.E. (2010) The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology, 117, 63-70.
https://doi.org/10.1016/j.ophtha.2009.06.051
|
|
[10]
|
Gong, Q., Gregg, E.W., Wang, J., et al. (2011) Long-Term Effects of a Randomised Trial of a 6-Year Lifestyle Intervention in Impaired Glucose Tolerance on Diabetes-Related Microvascular Complications: The China Da Qing Diabetes Prevention Outcome Study. Diabetologia, 54, 300-307.
https://doi.org/10.1007/s00125-010-1948-9
|
|
[11]
|
Nathan, D.M., Genuth, S., Lachin, J., et al. (1993) The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The New England Journal of Medicine, 329, 977-986.
https://doi.org/10.1056/NEJM199309303291401
|
|
[12]
|
(1994) Effect of Intensive Diabetes Treatment on the Development and Progression of Long-Term Complications in Adolescents with Insulin-Dependent Diabetes Mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. The Journal of Pediatrics, 125, 177-188.
https://doi.org/10.1016/S0022-3476(94)70190-3
|
|
[13]
|
Chew, E.Y., Ambrosius, W.T., Davis, M.D., et al. (2010) Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. The New England Journal of Medicine, 363, 233-244.
https://doi.org/10.1056/NEJMoa1001288
|
|
[14]
|
赵姝芝, 李涛, 郑冰清, 郑志. 糖尿病视网膜病变相关“代谢记忆”的研究进展[J]. 中华眼底病杂志, 2013, 29(1): 103-106.
|
|
[15]
|
Stratton, I.M., Adler, A.I., Neil, H.A., et al. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412.
https://doi.org/10.1136/bmj.321.7258.405
|
|
[16]
|
Matsuda, S., Tam, T., Singh, R.P., et al. (2014) The Impact of Metabolic Parameters on Clinical Response to VEGF Inhibitors for Diabetic Macular Edema. Journal of Diabetes and its Complications, 28, 166-170.
https://doi.org/10.1016/j.jdiacomp.2013.11.009
|
|
[17]
|
张聪, 徐丽. 糖化血红蛋白水平与糖尿病视网膜病变激光光凝术后黄斑水肿的相关性[J]. 中国医科大学学报, 2020, 49(11): 980-984.
|
|
[18]
|
Dodson, P.M. (2007) Diabetic Retinopathy: Treatment and Prevention. Diabetes and Vascular Disease Research, 4, S9-S11.
https://doi.org/10.3132/dvdr.2007.051
|
|
[19]
|
Keech, A.C., Mitchell, P., Summanen, P.A., et al. (2007) Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy (FIELD Study): A Randomised Controlled Trial. The Lancet, 370, 1687-1697.
https://doi.org/10.1016/S0140-6736(07)61607-9
|
|
[20]
|
Noonan, J.E., Jenkins, A.J., Ma, J.X., Keech, A.C., Wang, J.J. and Lamoureux, E.L. (2013) An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients with Diabetes. Diabetes, 62, 3968-3975.
https://doi.org/10.2337/db13-0800
|
|
[21]
|
Kim, J., Ahn, J.H., Kim, J.H., et al. (2007) Fenofibrate Regulates Retinal Endothelial Cell Survival through the AMPK Signal Transduction Pathway. Experimental Eye Research, 84, 886-893.
https://doi.org/10.1016/j.exer.2007.01.009
|
|
[22]
|
UK Prospective Diabetes Study Group (1998) Tight Blood Pres-sure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ, 317, 703-713.
https://doi.org/10.1136/bmj.317.7160.703
|
|
[23]
|
Wang, B., Wang, F., Zhang, Y., et al. (2015) Effects of RAS Inhibitors on Diabetic Retinopathy: A Systematic Review and Meta-Analysis. The Lancet Diabetes & Endocrinol-ogy, 3, 263-274.
https://doi.org/10.1016/S2213-8587(14)70256-6
|
|
[24]
|
Mauer, M., Zinman, B., Gardiner, R., et al. (2009) Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. The New England Journal of Medicine, 361, 40-51.
https://doi.org/10.1056/NEJMoa0808400
|
|
[25]
|
Chaturvedi, N., Porta, M., Klein, R., et al. (2008) Effect of Can-desartan on Prevention (DIRECT-Prevent 1) and Progression (DIRECT-Protect 1) of Retinopathy in Type 1 Diabetes: Randomised, Placebo-Controlled Trials. The Lancet, 372, 1394-1402.
https://doi.org/10.1016/S0140-6736(08)61412-9
|
|
[26]
|
中华医学会糖尿病学分会视网膜病变学组. 糖尿病视网膜病变防治专家共识[J]. 中华糖尿病杂志, 2018, 10(4): 241-247.
|
|
[27]
|
Zhang, X., Liu, W., Wu, S., Jin, J., Li, W. and Wang, N. (2015) Calcium Dobesilate for Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Science China Life Sciences, 58, 101-107.
https://doi.org/10.1007/s11427-014-4792-1
|
|
[28]
|
曲超, 杨宇峰, 闫振亮, 王成龙, 石岩. 芪明颗粒治疗糖尿病性黄斑水肿Meta分析[J]. 辽宁中医药大学学报, 2019, 21(2): 128-133.
|
|
[29]
|
Soffía, G.M., Einar, S., Fridbert, J. and Ingimundur, G. (1993) Retinal Vasoconstriction after Laser Treatment for Diabetic Macular Edema. American Journal of Ophthalmology, 115, 64-67
https://doi.org/10.1016/S0002-9394(14)73526-3
|
|
[30]
|
Lee, S.N., Chhablani, J., Chan, C.K., et al. (2013) Characterization of Microaneurysm Closure after Focal Laser Photocoagulation in Diabetic Macular Edema. American Journal of Ophthalmology, 155, 905-912.
https://doi.org/10.1016/j.ajo.2012.12.005
|
|
[31]
|
Yamada, Y., Suzuma, K., Fujikawa, A., Kumagami, T. and Kitaoka, T. (2013) Imaging of Laser-Photocoagulated Diabetic Microaneurysm with Spectral Domain Optical Coherence Tomography. Retina, 33, 726-731.
https://doi.org/10.1097/IAE.0b013e3182753960
|
|
[32]
|
(1985) Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group. Archives of Ophthalmology, 103, 1796-1806.
https://doi.org/10.1001/archopht.1985.01050120030015
|
|
[33]
|
Li, Z., Song, Y., Chen, X., Chen, Z. and Ding, Q. (2015) Biological Modulation of Mouse RPE Cells in Response to Subthreshold Diode Micropulse Laser Treatment. Cell Biochemistry and Biophysics, 73, 545-552.
https://doi.org/10.1007/s12013-015-0675-8
|
|
[34]
|
Edoardo, M., Silvia, B., Ferdinando, M., et al. (2020) Changes of Aqueous Humor Müller Cells’ Biomarkers in Human Patients Affected by Diabetic Macular Edema after Subthreshold Micropulse Laser Treatment. Retina, 40, 126-134.
https://doi.org/10.1097/IAE.0000000000002356
|
|
[35]
|
Al-Barki, A., Al-Hijji, L., High, R., et al. (2021) Comparison of Short-Pulse Subthreshold (532 nm) and Infrared Micropulse (810 nm) Macular Laser for Diabetic Macular Edema. Scientific Reports, 11, Article No. 14.
https://doi.org/10.1038/s41598-020-79699-9
|
|
[36]
|
Hamada, M., Ohkoshi, K., Inagaki, K., Ebihara, N. and Murakami, A. (2018) Subthreshold Photocoagulation Using Endpoint Management in the PASCAL® System for Diffuse Diabetic Macular Edema. Journal of Ophthalmology, 2018, Article ID: 7465794.
https://doi.org/10.1155/2018/7465794
|
|
[37]
|
Paula, S., Lebriz, A. and Sascha, F. (2017) A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders. Advances in Therapy, 34, 1528-1555.
https://doi.org/10.1007/s12325-017-0559-y
|
|
[38]
|
Kretz, F.T., Beger, I., Koch, F., Nowomiejska, K., Auffarth, G.U. and Koss, M.J. (2015) Randomized Clinical Trial to Compare Micropulse Photocoagulation versus Half-Dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy. Ophthalmic Surgery Lasers and Imaging Retina, 46, 837-843.
https://doi.org/10.3928/23258160-20150909-08
|
|
[39]
|
Mansouri, A., Sampat, K.M., Malik, K.J., Steiner, J.N. and Glaser, B.M. (2014) Efficacy of Subthreshold Micropulse Laser in the Treatment of Diabetic Macular Edema Is Influenced by Pre-Treatment Central Foveal Thickness. Eye (Lond), 28, 1418-1424.
https://doi.org/10.1038/eye.2014.264
|
|
[40]
|
Citirik, M. (2019) The Impact of Central Foveal Thickness on the Efficacy of Subthreshold Micropulse Yellow Laser Photocoagulation in Diabetic Macular Edema. Lasers in Medical Science, 34, 907-912.
https://doi.org/10.1007/s10103-018-2672-9
|
|
[41]
|
Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., et al. (2017) Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 237, 185-222.
https://doi.org/10.1159/000458539
|
|
[42]
|
Moisseiev, E., Abbassi, S., Thinda, S., Yoon, J., Yiu, G. and Morse, L.S. (2018) Subthreshold Micropulse Laser Reduces Anti-VEGF Injection Burden in Patients with Diabetic Macular Edema. European Journal of Ophthalmology, 28, 68-73.
https://doi.org/10.5301/ejo.5001000
|
|
[43]
|
方立建, 魏文斌. 康柏西普玻璃体腔内注射联合阈值下微脉冲激光治疗糖尿病黄斑水肿的临床研究[J]. 中华眼科医学杂志(电子版), 2020, 10(2): 90-96.
|
|
[44]
|
Blumenkranz, M.S., Yellachich, D., Andersen, D.E., et al. (2006) Semiautomated Patterned Scanning Laser for Retinal Photocoagulation. Retina, 26, 370-376.
https://doi.org/10.1097/00006982-200603000-00024
|
|
[45]
|
Kozak, I., Oster, S.F., Cortes, M.A., et al. (2011) Clini-cal Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILAS. Ophthalmology, 118, 1119-1124.
https://doi.org/10.1016/j.ophtha.2010.10.007
|
|
[46]
|
Ober, M.D., Kernt, M., Cortes, M.A. and Kozak, I. (2013) Time Required for Navigated Macular Laser Photocoagulation Treatment with the Navilas. Graefe’s Archive for Clinical and Experimental Ophthalmology, 251, 1049-1053.
https://doi.org/10.1007/s00417-012-2119-0
|
|
[47]
|
Neubauer, A.S., Langer, J., Liegl, R., et al. (2013) Navigated Macular Laser Decreases Retreatment Rate for Diabetic Macular Edema: A Comparison with Conventional Macular Laser. Clinical Ophthalmology, 7, 121-128.
https://doi.org/10.2147/OPTH.S38559
|
|
[48]
|
Liu, K., Song, Y., Xu, G., et al. (2019) Conbercept for Treatment of Neovascular Agerelated Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. American Journal of Ophthalmology, 197, 156-167.
https://doi.org/10.1016/j.ajo.2018.08.026
|
|
[49]
|
Sacconi, R., Giuffrè, C., Corbelli, E., Borrelli, E., Querques, G. and Bandello, F. (2019) Emerging Therapies in the Management of Macular Edema: A Review. F1000Research, 8, F1000.
https://doi.org/10.12688/f1000research.19198.1
|
|
[50]
|
Cai, S. and Bressler, N.M. (2017) Aflibercept, Bevacizumab or Ranibizumab for Diabetic Macular Oedema: Recent Clinically Relevant Findings from DRCR.net Protocol T. Current Opinion in Ophthalmology, 28, 636-643.
https://doi.org/10.1097/ICU.0000000000000424
|
|
[51]
|
Rahimy, E., Shahlaee, A., Khan, M.A., et al. (2016) Conversion to Aflibercept after Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. American Journal of Ophthalmology, 164, 118-27.e2.
https://doi.org/10.1016/j.ajo.2015.12.030
|
|
[52]
|
Li, X., Dai, H., Li, X., et al. (2019) Efficacy and Safety of Ranibizumab 0.5 mg in Chinese Patients with Visual Impairment Due to Diabetic Macular Edema: Results from the 12-Month REFINE Study. Graefe’s Archive for Clinical and Experimental Ophthalmology, 257, 529-541.
https://doi.org/10.1007/s00417-018-04213-x
|
|
[53]
|
Khanani, A.M., Callanan, D., Dreyer, R., et al. (2021) End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 5, 775-787.
https://doi.org/10.1016/j.oret.2020.11.004
|
|
[54]
|
Sharma, A., Parachuri, N., Kumar, N., et al. (2020) Brolucizumab-Key Learnings from HAWK and HARRIER. Eye (Lond), 34, 1318-1320.
https://doi.org/10.1038/s41433-020-0842-z
|
|
[55]
|
Garweg, J.G. (2020) A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impair-ment Due to Diabetic Macular Edema (KITE). Klinische Monatsblätter für Augenheilkunde, 237, 450-453.
https://doi.org/10.1055/a-1101-9126
|
|
[56]
|
Lampen, S., Khurana, R.N., Noronha, G., Brown, D.M. and Wykoff, C.C. (2018) Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients with Diabetic Macular Edema. Ophthalmic Surgery, Lasers and Imaging Retina, 49, 692-697.
https://doi.org/10.3928/23258160-20180831-07
|
|
[57]
|
Pacella, F., Ferraresi, A.F., Turchetti, P., et al. (2016) Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up. Ophthalmology and Eye Diseases, 8, 11-16.
https://doi.org/10.4137/OED.S38028
|
|
[58]
|
Maturi, R.K., Glassman, A.R., Liu, D., et al. (2018) Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients with Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmology, 136, 29-38.
https://doi.org/10.1001/jamaophthalmol.2017.4914
|
|
[59]
|
Epstein, D., Mirabelli, P. and Lövestam Adrian, M. (2020) Treatment Algorithm with Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Acta Ophthalmologica, 98, e528-e529.
https://doi.org/10.1111/aos.14339
|
|
[60]
|
El-Ghrably, I.A., Saad, A. and Dinah, C. (2015) A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber. Ophthalmology and Therapy, 4, 129-133.
https://doi.org/10.1007/s40123-015-0035-1
|
|
[61]
|
Wykoff, C.C., Chakravarthy, U., Campochiaro, P.A., Bailey, C., Green, K. and Cunha-Vaz, J. (2017) Long-Term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology, 124, 440-449.
https://doi.org/10.1016/j.ophtha.2016.11.034
|
|
[62]
|
Haller, J.A., Qin, H., Apte, R.S., et al. (2010) Vitrectomy Outcomes in Eyes with Diabetic Macular Edema and Vitreomacular Traction. Ophthalmology, 117, 1087-1093.e3.
https://doi.org/10.1016/j.ophtha.2009.10.040
|
|
[63]
|
Jackson, T.L., Nicod, E., Angelis, A., Grimaccia, F., Pringle, E. and Kanavos, P. (2017) Pars Plana Vitrectomy for Diabetic Macular Edema: A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina, 37, 886-895.
https://doi.org/10.1097/IAE.0000000000001280
|
|
[64]
|
Meng, W., Li, R. and Xie, X. (2019) Conbercept and Retinal Photocoagulation in the Treatment of Diabetic Macular Edema. Pakistan Journal of Medical Sciences, 35, 1493-1498.
https://doi.org/10.12669/pjms.35.6.512
|
|
[65]
|
Hernández, C., Dal Monte, M., Simó, R. and Casini, G. (2016) Neuroprotection as a Therapeutic Target for Diabetic Retinopathy. Journal of Diabetes Research, 2016, Article ID: 9508541.
https://doi.org/10.1155/2016/9508541
|
|
[66]
|
Tombran-Tink, J. (2005) The Neuroprotective and Angiogenesis Inhibitory Serpin, PEDF: New Insights into Phylogeny, Function, and Signaling. Frontiers in Bioscience, 10, 2131-2149.
https://doi.org/10.2741/1686
|
|
[67]
|
Satari, M., Aghadavod, E., Mirhosseini, N. and Asemi, Z. (2019) The Effects of microRNAs in Activating Neovascularization Pathways in Diabetic Retinopathy. Journal of Cellular Biochemistry, 120, 9514-9521.
https://doi.org/10.1002/jcb.28227
|
|
[68]
|
Campochiaro, P.A., Channa, R., Berger, B.B., et al. (2013) Treatment of Diabetic Macular Edema with a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study. American Journal of Ophthalmology, 155, 697-704, 704.e1-2.
https://doi.org/10.1016/j.ajo.2012.09.032
|
|
[69]
|
Kunimoto, D., Yoon, Y.H., Wykoff, C.C., et al. (2020) Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology, 127, 1331-1344.
https://doi.org/10.1016/j.ophtha.2020.03.035
|
|
[70]
|
Shaw, L.T., Mackin, A., Shah, R., et al. (2020) Risuteganib—A Novel Integrin Inhibitor for the Treatment of Non-Exudative (Dry) Age-Related Macular Degeneration and Diabetic Macular Edema. Expert Opinion on Investigational Drugs, 29, 547-554.
https://doi.org/10.1080/13543784.2020.1763953
|
|
[71]
|
Bhatwadekar, A.D., Kansara, V., Luo, Q. and Ciulla, T. (2020) Anti-Integrin Therapy for Retinovascular Diseases. Expert Opinion on Investigational Drugs, 29, 935-945.
https://doi.org/10.1080/13543784.2020.1795639
|
|
[72]
|
Boyer, D.S., Gonzalez, V.H., Kunimoto, D.Y., et al. (2021) Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial. Ophthalmic Surgery, Lasers and Imaging Retina, 52, 327-335.
https://doi.org/10.3928/23258160-20210528-05
|
|
[73]
|
Wykoff, C.C., Abreu, F., Adamis, A.P., et al. (2022) Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-Masked, Phase 3 Trials. The Lancet, 399, 741-755.
https://doi.org/10.1016/S0140-6736(22)00018-6
|